Rockville, MD. Rise Therapeutics today announced that Montgomery County has issued Rise Therapeutics a $25,000 Small Business Innovative Research (SBIR) grant matching award. This funding was awarded based upon Montgomery County’s SBIR/STTR Matching Grant Program and will be used to further Rise Therapeutics’ research project efforts to develop novel microbiome-based medicines,
“The Montgomery County SBIR matching funds program has been an important help supporting our programs here at Rise,” said Dr. Gary Fanger, President and CEO of Rise Therapeutics said. “We are excited to utilize these funds as a financial extension to our Phase I NIH SBIR.”
The microbiome is correlated with human health, but the mechanisms for this and the specific commensal bacteria strains have not been elucidated and limit their translation into new therapeutics. Discovery of novel pathways and targets related to how the microbiome regulate host physiology and affect disease conditions allows Rise to leverage its oral drug delivery platform to generate novel immune therapies.
Rise Therapeutics is an experienced oral therapeutics developer focused on launching promising products to the patients who need them the most. Rise Therapeutics has a robust oral therapeutics pipeline for which it is rapidly progressing into clinical studies.
About Rise Therapeutics
Rise Therapeutics is an emerging, privately held company located in Rockville, Maryland which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. Unlike traditional biological therapies which require injection or infusion, Rise Therapeutics’ delivery platform allows simple, convenient, and cost-effective oral capsule delivery of targeted protein therapy. Our drug development focus is driven by new microbiome-related discoveries enabling development of targeted, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, cancer, and infection. In the context of its expertise in synthetic biology medicine, proprietary TPX oral drug delivery platform, and clinical GMP manufacturing capabilities, Rise is creating and rapidly advancing life changing cellular-based medicines to the market. For more information, go to www.risetherapeutics.com.